This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
Integration of Lutetium-177 and the Value of Shared Decisions with Practice Stakeholders - Jeffrey Zemencik
Details
Phillip Koo interviews Jeffrey Zemencik about the challenges and considerations of integrating the PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) treatment into large urology practices. Mr. Zemencik emphasizes the importance of a multi-disciplinary approach, involving stakeholders from various departments like operations and revenue cycle. He underscores the billing and reimbursement guide prov...
Expanding the Nuclear Hot Lab to Accommodate Lutetium-177 - Lyanne Gomez
Details
Phillip Koo tours the "hot lab" at an infusion center, guided by Lyanne Gomez, a nuclear medicine technologist. The conversation provides an in-depth look at the equipment used for handling PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan). Lyanne explains the functions of existing equipment, such as the wipe calibrator and dose calibrator. She also introduces new additions required for PLUVICTO,...
Finding the Right Patient for Lutetium-177 PSMA Treatment - Kara Cossis
Details
Phillip Koo converses with Kara Cossis about the critical aspect of patient selection for PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) treatment. Ms. Cossis outlines the criteria for identifying suitable candidates, emphasizing the role of castrate-resistant metastatic prostate cancer, disease burden, and eligibility based on scans. She also discusses the logistics of obtaining PSMA PET scans...
Coordinating & Transitioning Patient Care for Patients Who Receive Lutetium-177 - Elizabeth Davis
Details
Phillip Koo interviews Elizabeth Davis to discuss the crucial role of care coordination in the PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) program. Ms. Davis outlines the step-by-step process she follows once a physician decides a patient should receive PLUVICTO treatment. From handling paperwork and insurance approvals to ordering the drug and scheduling injections, Ms. Davis ensures a seam...
A Urologist’s Multidisciplinary Approach to Clinical Management of the Patient Receiving Lutetium-177 - Benjamin Lowentritt
Details
In this discussion, Phillip Koo interviews Benjamin Lowentritt about the complexities of integrating a PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) program into a large urology practice. Dr. Lowentritt emphasizes the value of patient selection, particularly for those who are post-chemotherapy. He outlines how his team manages the transition of patients from medical oncologists to their specia...
Radiation Safety Considerations for the Authorized User when Operationalizing Lutetium-177 in the Urology Clinic - Robert Brookland
Details
Phillip Koo converses with Robert Brookland about the intricacies of implementing a PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) program. Dr. Brookland, who serves as both the radiation safety officer and the authorized user, elaborates on the pivotal role of an authorized user in patient selection, treatment monitoring, and patient counseling. He also discusses the importance of experience w...
Multidisciplinary Transitions in Care for Patients Receiving Lutetium-177 - Benjamin Lowentritt & Robert Brookland
Details
Phillip Koo hosts Benjamin Lowentritt, Urologist, and Robert Brookland, Radiation Oncologist, to discuss the multidisciplinary approach to patient care with PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan). Dr. Lowentritt outlines the seamless transition from identifying suitable candidates for PLUVICTO to referring them to Dr. Brookland for further consultation and treatment. The discussion delv...
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free